Skip to main content
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

Mexedrone

This article is a stubmissing:
Pharmacology
Tolerance
History & Culture
Mexedrone molecule structureMexedrone molecule structure
3-Methoxy-2-(methylamino)-1-(p-tolyl)propan-1-one
4-MMC-MeO
Psychoactive Class
StimulantEntactogen

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~50 mg
Light50-80 mg
Moderate80-120 mg
Strong120-200 mg
Heavy200+ mg

Duration

Onset5 minutes
Total3 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

Physical euphoriaTactile enhancementDehydrationIncreased perspirationTemperature regulation suppression

Cognitive

Thought accelerationThought connectivity

Auditory

Enhancements
Forked from Subjective Effect Documentation work byJosie Kins August 2016.

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Mandelin(MD)
yellow2 → orange2 → red2 → brown2 → yellow2
Liebermann(LB)
white → yellow1 → orange1
Simons(SI)
orange1 → black2 → blue1 → blue2
Zimm(ZI)
white → brown2
Powered by PROtestkit.eu

Pharmacology

Pharmacology not written up yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

5-HTPAlcoholCocaineDXMDissociativesMAOIsMDMAMXENBOMe compoundsSNRIsSSRIsSerotonin releasersStimulantsTramadol
Powered by TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Addiction & Dependence

Psychological

Moderate

Long-term use may carry moderate addiction risk, high abuse potential, and the possibility of psychological dependence for some users. Once dependence is present, suddenly stopping use may produce cravings and withdrawal effects.

Psychosis Risk

Combinations with dissociatives carry a risk of delusions, mania and psychosis, though the risk from mexedrone alone is not characterized.

History & Culture

History & Culture not written up yet

Legality

By Country

Illegal2
Sweden flagSwedenMexedrone is illegal
Switzerland flagSwitzerlandIllegal

References

Source Pages

  1. Bluelight: Mexedrone Discussion Thread
  2. Drug Users Bible by Dominic Milton Trott
  3. Isomer Design (TiHKAL/PiHKAL)
  4. PsychonautWiki
  5. TripSit Factsheets
  6. Wikipedia

Citations

  1. Betäubungsmittelverzeichnisverordnung (BetmVV-EDI), Stand am 13. März 2026, Anhang 6, Verzeichnis e. fedlex.data.admin.ch (n.d.). https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/363/20260313/de/html/fedlex-data-admin-ch-eli-cc-2011-363-20260313-de-html-3.html1
  2. Verordnung über die Betäubungsmittelkontrolle (Betäubungsmittelkontrollverordnung, BetmKV), Stand am 23. Januar 2023, Art. 3. fedlex.admin.ch (n.d.). https://www.fedlex.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/362/20230123/de/html/fedlex-data-admin-ch-eli-cc-2011-362-20230123-de-html-3.html1
  3. Bundesgesetz über die Betäubungsmittel und die psychotropen Stoffe (Betäubungsmittelgesetz, BetmG), Stand am 1. September 2023, Art. 7 und Art. 20. fedlex.data.admin.ch (n.d.). https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/1952/241_241_245/20230901/de/html/fedlex-data-admin-ch-eli-cc-1952-241_241_245-20230901-de-html-8.html1

Further Reading

  1. McLaughlin et al. (2017) - Synthesis, characterization and monoamine transporter activity of mexedrone
  2. McLaughlin et al. (2017) - Synthesis, characterization and monoamine transporter activity of mexedrone
  3. Roberts et al. (2017) - 11 analytically confirmed cases of mexedrone use among polydrug users
  4. WEDINOS Mexedrone Sample Analysis

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Mexedrone article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.